Professional
Added to YB: 2025-06-27
Pitch date: 2025-06-25
LLY [bullish]
Eli Lilly and Company
+29.89%
current return
Author Info
No bio for this author
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$791.05
Price Target
1.2K (+16%)
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Citi Reiterates Buy on $LLY, PT $1,190
LLY: Citi (Meacham) reiterates Buy, PT $1,190. Orforglipron (2026e launch) oral obesity drug to reshape market; modeled >$40B 2030+ sales vs consensus ~$25B. LillyDirect platform could add ~$15B opportunity by linking consumer visibility with global access. Potential for accelerated OUS rollout using centralized payment model.
Read full article (1 min)